Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 20/20 | 0.72 |
| ▸ | PTGIR | P43119 | 1/20 | 0.57 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269788 | 0.93 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL2269382 | 0.92 | PTGDR2 (0.81) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1782651 | 0.90 | PTGDR2 (0.66) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1784633 | 0.88 | PTGDR2 (0.63) | PTGDR2 | |
| SCHEMBL1466115 | 0.88 | PTGDR2 (0.84) | PTGDR2 | |
| SCHEMBL1785449 | 0.87 | PTGDR2 (0.68) | PTGDR2 | |
| SCHEMBL4761775 | 0.87 | PTGDR2 (0.79) | PTGDR2PTGIRPTGDR | |
| SCHEMBL1785920 | 0.87 | PTGDR2 (0.62) | PTGDR2 | |
| SCHEMBL1783452 | 0.85 | PTGDR2 (0.62) | PTGDR2 | |
| SCHEMBL2272823 | 0.84 | PTGDR2 (0.78) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268878-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-09-18 | — | — | US | disclosed |
| CN-101506159-B | Compounds having CRTH2 antagonist activity | OXAGEN LTD | 2012-08-22 | — | — | CN | disclosed |
| US-20110268693-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| US-7999119-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2011-08-16 | — | — | US | disclosed |
| US-20100035956-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| CN-101506159-A | Compounds having CRTH2 antagonist activity | OXAGEN LTD (GB) | 2009-08-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268693-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH1, HRH4 | PTGDR2 122/4885PTGIR 290/4885PTGDR 186/4885 |
| US-20100035956-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH1, HRH4 | PTGDR2 122/4885PTGIR 290/4885PTGDR 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.